Rachel Tanner 💉

Incredibly excited to be leading this new @IneosOxford-funded interdisciplinary consortium developing new #drugs for #AMR #TB! 🫁🦠💊💉 ox.ac.uk/news/2025-02-2…

Two months to go until the IOI ECR Conference 2026! Have you registered for your free place yet? Featuring talks from across disciplines, the conference will be an opportunity to share knowledge and make connections. #AMR Register now ➡️ ineosoxford.ox.ac.uk/event/ioi-earl… #AntimicrobialResistance #IOIECR26

POV: you are a young woman celebrating a recent academic success

Journals can’t find peer reviewers. Preprints aren’t taken seriously. Garbage papers slip through peer review. Meantime, AI is slowly taking over. Nature describes the current situation. I highly recommend reading the article. 📍 The summary (+ my comments): 1. We are facing a SIGNIFICANT overload on reviewers. Fatigue is epidemic. Few scientists have time for much peer review. As a result, manuscript turnaround times are chaos. They’re unpredictable and painfully slow. 2. Grant and facility proposals demand massive peer review too. They push the system even further. 3. Review quality is decreasing. Rigor is inconsistent. Technical aspects are poorly assessed. 4. Gatekeeping and bias are very real (we all know how manuscripts are rejected due to competition & jealousy). It causes a growing dissatisfaction among scientists. 5. Paid reviewing does NOT automatically improve the acceptance rate. Trials show mixed results. For example, acceptance rates barely increased from 48% to 53% for Critical Care Medicine. The quality of PR remained the same. But for Biology Open, the PR process has become much faster. In either case, paid reviews are very hard to scale business-wise. 6. Distributed Peer Review is becoming more popular. Some funding agencies now require applicants to review peers’ proposals. But to to eliminate bias in it? I don’t know. ❗ There’re no simple solutions. As a careful observer, I think that the complex picture is evolving along the following trajectory: AI-assisted peer view (AI pre-screening, AI PR-assistant, AI audition of peer reviews) + Community reviewing + Some form of compensation + Involvement of wider community in PR lists (not only most recognized scientists) What’s your view on it?

New paper: @Salem_Almujri identified new #Mtb antigens using #immunopeptidomics, screened them using #MGIA, identified metE as promising, & confirmed in murine challenge studies 🤩 A potential new #TB #vaccine candidate in the making 💉 Congrats Salem! 👏 frontiersin.org/journals/immun…

This should be required reading by all graduate students and postdocs | A brief guide to statistical analysis of grouped data in preclinical research nature.com/articles/s4225…

New #MGIA paper in collaboration with @UCT_news 🇿🇦 onlinelibrary.wiley.com/doi/10.1111/im… Poorer control of mycobacterial growth following #BCG #vaccination administered during an acute malarial infection compared to BCG only or BCG after blood-stage #malaria infection 💉🦟🩸

It was my pleasure to be interviewed by @immunoafrica_ for this episode of Immunology to TB. Here I share my journey as a scientist and our contributions to TB vaccine development.

Are you interested in #TB and have experience in #modelling infectious diseases? Come join us in the fun, supportive, and world-leading TB Modelling Group at @LSHTM ! We have a 1 year Research Fellow position (with possible extension) Closing date of 30 May 2025 👉 jobs.lshtm.ac.uk/vacancy.aspx?r…

Wondering how #BCG #vaccination confers protection against unrelated #pathogens? 💉🦠 Of course you are! Check out our new #SystematicReview on #immune mechanisms underlying #heterologous protection, led by very talented Med student Louis Torracinta: frontiersin.org/journals/immun…

We're recruiting! Looking for an experienced and motivated #postdoctoral researcher to join the #TannerLab as part of our @IneosOxford funded consortium for the development of new #TB #drugs 🫁💊 my.corehr.com/pls/uoxrecruit…

TWO postdoc positions in Computational Microbiology and/or biochemistry. Join our interdisciplinary group in the new Life and Mind Building @OxfordBiology, @UniofOxford, @IneosOxford Please apply and share this post: jobs.ac.uk/job/DMP641/pos…

Latest research published by @satvi_uct reporting results from the Phase 2a MTBVAC TB Vaccine trial study conducted appearing in the @eBioMedicine. @UCTIDM @UCTHealthSci @CarlosMTBVAC sciencedirect.com/science/articl…

Free online Q&A on writing non-fiction with bestselling author Angela Saini! 30th April, from Spread the Word spreadtheword.org.uk/events/angela-…

Our Vaccine Engagement Day is on 26 March 2025! Let's #CelebrateVaccines to strengthen public understanding and empower informed decisions about vaccines 🎉 Get involved by posting on social media to highlight the successes of vaccines! 🌟 bit.ly/3Rasp6s

Modelling on potential impact of Tuberculosis globally shows the US funding cuts would result in 2.2 million additional TB deaths and 10.6 million additional TB cases during 2025-30. A Deadly Equation: The Global Toll of US TB Funding Cuts | medRxiv @StopTB @SahuSuvanand

Massive $200 million TB research programme derailed by US funding cuts spotlightnsp.co.za/2025/03/04/mas…

Do you have Yr12 students in state school interested in studying Biology with us? @BalliolOxford has the event for them. forms.office.com/pages/response…

Tuberculosis is a curable disease, yet millions of people fall ill or die of TB due to antimicrobial resistance. Now a consortium led by Oxford Biology @ProfTtweetsTB aims to develop new therapies to tackle TB thanks to a £5m grant from @IneosOxford bit.ly/4kcGxcL